{"id":312,"date":"2013-07-19T16:19:09","date_gmt":"2013-07-19T07:19:09","guid":{"rendered":"http:\/\/120.29.164.89\/?p=312"},"modified":"2023-08-29T11:07:12","modified_gmt":"2023-08-29T02:07:12","slug":"312","status":"publish","type":"post","link":"https:\/\/www.peptide.co.jp\/en\/new-product\/312.html","title":{"rendered":"Urotensin II (Rat)"},"content":{"rendered":"<p><b>[Potent Vasoconstrictor]<\/b><\/p>\n<p>Urotensin II (U-II) is a disulfide-linked small peptide initially isolated from fish urophysis. Subsequently, the cDNA sequence encoding the human U-II precursor was determined, and the corresponding mRNA was found to exist predominantly in spinal cord [<i>Proc. Natl. Acad. Sci. USA<\/i>, <b>95<\/b>, 15803 (1998)]. Human U-II, then, was revealed to be an agonist for the orphan receptor GPR14 and exerts a strong vasoconstricting activity in the isolated thoracic<img loading=\"lazy\" src=\"\/wp-content\/uploads\/2013\/07\/hut-ii.gif\" alt=\"hut-ii\" width=\"156\" height=\"65\" class=\"alignright size-full wp-image-2199\" \/> aorta of rat [<i>Nature<\/i>, <b>401<\/b>, 282 (1999)]. The potency of vasoconstriction of U-II is an order of magnitude greater than that of endothelin-1, making human U-II the most potent mammalian vasoconstrictor identified so far.<\/p>\n<p>Following the sequence determination of human U-II, the same group reported the corresponding rat peptide cDNA sequence [<i>FEBS Lett<\/i>., <b>457<\/b>, 28 (1999)]. When we look at the deduced peptide sequence of rat prepro-U-II, there are two double basic sites at its C-terminal region, which might be the enzymatic cleavage sites for yielding the mature peptide of rat U-II. We chose the shorter peptide of 14 amino acid residues with pyroglutamic acid modification for Gln<sup>110<\/sup> as the possible candidate for rat U-II and chemically synthesized it. Synthetic [Pyr<sup>110<\/sup>]-prepro-U-II (110-123) was confirmed to have a vasoconstricting activity as potent as that of human peptide in the isolated thoracic aorta of rat (unpublished result). Therefore, <img loading=\"lazy\" src=\"\/wp-content\/uploads\/2013\/07\/rut-ii.gif\" alt=\"rut-ii\" width=\"215\" height=\"67\" class=\"alignright size-full wp-image-2212\" \/>we tentatively named this peptide rat U-II in our catalog, although the mature form of rat U-II remains to be determined. Recently, Davenport AP &amp; Maguire JJ have predicted the sequence of rat or mouse U-II as prepro-U-II (110-123) [<i>Trends Pharmacol. Sci.<\/i>, <b>21<\/b>, 80 (2000)].<\/p>\n<table style=\"width: 90%\" border=\"1\">\n<tbody>\n<tr>\n<td align=\"center\">Code<\/td>\n<td align=\"center\">Compound<\/td>\n<td align=\"center\">Quantity<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4371-v\">4371-v<\/a><\/td>\n<td>Urotensin II (Rat)<\/td>\n<td align=\"center\">0.5 mg vial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table style=\"width: 90%\" border=\"1\">\n<tbody>\n<tr align=\"center\">\n<td>Code<\/td>\n<td>Compound<\/td>\n<td>Quantity<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4365-v\">4365-v<\/a><\/td>\n<td>Urotensin II (Human)<\/td>\n<td align=\"center\">0.5 mg vial<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=14365-v\">14365-v<\/a><\/td>\n<td>Urotensin II (Human) Antiserum<\/td>\n<td align=\"center\">0.05 ml vial<\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\"><\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4327-s\">4327-s<\/a><\/td>\n<td>Urocortin (Rat)<\/td>\n<td align=\"center\">0.1 mg vial<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4328-s\">4328-s<\/a><\/td>\n<td>Urocortin (Human)<\/td>\n<td align=\"center\">0.1 mg vial<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4111-s\">4111-s<\/a><\/td>\n<td>CRF (Ovine)<\/td>\n<td align=\"center\">0.1 mg vial<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4136-s\">4136-s<\/a><\/td>\n<td>CRF (Human, Rat)<\/td>\n<td align=\"center\">0.1 mg vial<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=14136-v\">14136-v<\/a><\/td>\n<td>CRF (Human) Antiserum<\/td>\n<td align=\"center\">0.05 ml vial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Potent Vasoconstrictor<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/312"}],"collection":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/comments?post=312"}],"version-history":[{"count":2,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/312\/revisions"}],"predecessor-version":[{"id":4957,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/312\/revisions\/4957"}],"wp:attachment":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/media?parent=312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/categories?post=312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/tags?post=312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}